TMS for Schizophrenia

What is Schizophrenia and How TMS Helps

Schizophrenia affects about 1% of people worldwide. It disrupts thinking, perception, emotion, and behavior in ways that make daily life profoundly difficult. The symptoms split into two broad categories. Positive symptoms — an excess or distortion of normal function: hallucinations, delusions, disorganized thinking. Negative symptoms — a diminishment of normal function: flat affect, avolition (no motivation), anhedonia (inability to feel pleasure), social withdrawal.

The brain changes are widespread. Auditory verbal hallucinations — hearing voices, the most common type — are tied to hyperactivity in the left temporoparietal junction (TPJ) and superior temporal gyrus. These regions normally process language and help you distinguish your own inner speech from external sounds. Negative symptoms connect to hypoactivity in the dorsolateral prefrontal cortex (DLPFC), mirroring what we see in major depression. Add disrupted frontal-temporal connectivity, abnormal dopamine signaling, and impaired glutamate neurotransmission, and you have the complex picture of this disorder.

Antipsychotic medications are the treatment backbone, but they have real limitations. First-generation antipsychotics reduce positive symptoms effectively but often cause debilitating movement disorders. Second-generation antipsychotics improved that profile but still fail to adequately address negative symptoms in most people. And about 30% of people with auditory hallucinations keep hearing voices despite adequate medication trials. That’s treatment-resistant auditory hallucinations — and it’s exactly where TMS comes in.

TMS addresses these gaps by directly modulating the dysfunctional circuits. Low-frequency TMS to the hyperactive left TPJ calms overexcited language processing regions, reducing hallucination severity. High-frequency TMS to the underactive left DLPFC boosts prefrontal function, targeting negative symptoms. These circuit-specific approaches work alongside antipsychotic medication — they don’t replace it.

How TMS Works for Schizophrenia

Different symptom domains, different protocols, different brain targets.

For auditory hallucinations: Low-frequency rTMS (1 Hz) applied to the left TPJ — the junction of the posterior superior temporal gyrus and inferior parietal lobule. Neuroimaging consistently shows this region is hyperactive during voice-hearing. The inhibitory effect of 1 Hz stimulation turns down that pathological hyperactivity, quieting the aberrant language processing that produces the experience of hearing voices. Typical parameters: 1 Hz at 90-110% motor threshold, 900-1,200 pulses per session, 15-20 minutes.

For negative symptoms: High-frequency rTMS (10-20 Hz) to the left DLPFC, using the same excitatory logic as depression TMS. Negative symptoms and depression share neurobiology — reduced prefrontal activity, diminished motivation, impaired reward processing. Boosting DLPFC excitability may improve motivation, emotional expressiveness, and social engagement. Typical parameters mirror depression protocols: 10 Hz at 120% motor threshold, 3,000 pulses per session.

Sequential bilateral protocols are an emerging approach — targeting both symptom domains in the same treatment course. Low-frequency TPJ stimulation followed by high-frequency DLPFC stimulation in the same session or alternating sessions. Addresses the full spectrum of treatment-resistant symptoms, though research is still early.

Deep TMS using H-coils can stimulate broader cortical areas and may reach the medial prefrontal and cingulate regions also implicated in schizophrenia. Preliminary studies suggest potential advantages for negative symptoms in particular.

Clinical Evidence and Success Rates

After depression, schizophrenia is one of the most studied psychiatric TMS applications. Over 100 published clinical trials.

Auditory hallucinations — the strongest evidence:

• A 2020 meta-analysis of 23 RCTs found low-frequency rTMS to the left TPJ produced statistically significant and clinically meaningful reductions in hallucination severity
• About 30-50% of people with treatment-resistant auditory hallucinations experience meaningful reduction in voice-hearing after a TMS course
• The large multicenter THETA study showed significantly greater hallucination reduction with active TMS vs. sham
• Effects typically last 2-8 weeks after completing treatment, with some people experiencing longer remissions
• TMS works best as an add-on to antipsychotic medication, not standalone
• Responders tend to show improvement by the end of week 2

Negative symptoms — moderate evidence:

• A 2021 meta-analysis found a small but statistically significant effect of high-frequency DLPFC stimulation on negative symptoms
• Improvements show up most in motivation, social function, and emotional expression
• Response rates are lower than for hallucinations — roughly 20-35% show meaningful improvement
• Effects may need maintenance treatment to sustain
• Results across studies are more variable. This remains a tough treatment target.

Cognitive symptoms:

• Some studies report secondary improvements in working memory and attention with DLPFC protocols
• Cognitive benefits are modest and inconsistent across trials
• Research continues to explore whether TMS can meaningfully improve the cognitive deficits that are often the most functionally impairing part of schizophrenia

TMS is not FDA-approved for schizophrenia or any psychotic disorder. It’s used as an investigational or off-label add-on at specialized centers.

Who Qualifies for TMS Treatment

Appropriate candidates have specific clinical profiles:

For auditory hallucinations:

• Persistent voices despite adequate trials of at least two antipsychotics (including clozapine if tolerated)
• Hallucinations causing significant distress or functional impairment
• Stable psychiatric status — not in acute psychotic crisis
• Ability to stay still and cooperate during sessions

For negative symptoms:

• Prominent flat affect, avolition, or social withdrawal significantly impairing daily life
• Negative symptoms that haven’t responded to antipsychotic optimization or add-on treatments
• Ability to attend daily sessions over several weeks

Contraindications specific to schizophrenia:

• Clozapine deserves special attention. It significantly lowers seizure threshold, and combining it with TMS adds risk. Not an absolute contraindication — but requires careful risk-benefit analysis and potentially lower stimulation intensities.
• Severe disorganization preventing the person from sitting still, following instructions, or tolerating the coil
• Active suicidality or imminent safety concerns — these need immediate psychiatric management first
• Standard TMS contraindications — metallic head implants, cardiac pacemakers, active seizure disorder
• Paranoid beliefs about the treatment — if someone is deeply convinced the device will harm them or read their thoughts, the therapeutic relationship may not support safe treatment

All candidates should be evaluated by a psychiatrist experienced with schizophrenia, and TMS should be coordinated with whoever manages the antipsychotic regimen.

What to Expect During Treatment

A typical course: daily sessions Monday through Friday for 3-4 weeks (15-20 sessions). Negative symptom protocols may extend to 4-6 weeks (20-30 sessions), similar to depression.

Before treatment: A thorough psychiatric evaluation confirms the diagnosis, documents treatment history, and establishes baseline symptom severity using standardized measures — the Auditory Hallucination Rating Scale for voices, the Scale for the Assessment of Negative Symptoms for negative symptoms. Medication review ensures all pharmacological options have been reasonably explored.

First session: Motor threshold determination via motor cortex stimulation. Then the coil is positioned over the target — left TPJ for hallucinations, left DLPFC for negative symptoms. Some centers use MRI-guided neuronavigation for more precise TPJ targeting, which may improve results.

During sessions: You sit in a comfortable chair, fully awake. For hallucination protocols (1 Hz), you hear a slow, rhythmic clicking — one pulse per second — and feel gentle tapping. Sessions run about 15-20 minutes. For negative symptom protocols (10 Hz), rapid bursts with pauses between trains, lasting 20-30 minutes. Both are generally tolerable, though early sessions can be mildly uncomfortable.

What improvement looks like:

• Hallucinations: Changes typically emerge during weeks 2-3. Voices may become quieter, less frequent, less distressing, or easier to ignore. Complete cessation is possible but not typical — most responders get a meaningful reduction, not elimination.
• Negative symptoms: More gradual, more subtle. Improved motivation, more social interest, greater emotional responsiveness developing over weeks 3-6. Family members and clinicians often notice changes before the person themselves does.

Side Effects and Safety

TMS is generally safe in schizophrenia, with a side effect profile similar to depression treatment:

• Scalp discomfort at the stimulation site (20-35%)
• Mild headache after treatment (10-20%)
• Lightheadedness immediately after sessions
• Jaw muscle twitching during stimulation (particularly with TPJ protocols)
• Transient tinnitus worsening in people with pre-existing tinnitus (rare)

Seizure risk needs careful attention here. The baseline TMS risk is about 0.1%, but several factors common in schizophrenia increase it:

• Clozapine and other antipsychotics that lower seizure threshold
• Concurrent antidepressants
• Sleep deprivation (common in schizophrenia)
• Substance use (particularly stimulants and alcohol withdrawal)

These compounding risks are managed through medication review, screening, and in some protocols, EEG monitoring during early sessions. With proper precautions, published studies haven’t reported significantly elevated seizure rates.

Compared to adding another antipsychotic or increasing doses — with their weight gain, metabolic syndrome, movement disorders, and sedation — TMS has a much cleaner side effect profile. That matters especially for people already carrying a heavy medication burden.

One thing that cannot be overstated: TMS should never replace antipsychotic medication. Stopping antipsychotics can trigger psychotic relapse. TMS is always an add-on in schizophrenia.

TMS Devices Used for Schizophrenia

• MagVenture MagPro — The most commonly used system in schizophrenia research worldwide. Supports precise low-frequency protocols for TPJ stimulation. Used in many of the landmark hallucination trials.
• Magstim Rapid2 and Super Rapid2 — Widely used in European schizophrenia studies. Reliable for the repetitive low-frequency stimulation hallucination protocols require.
• BrainsWay Deep TMS — H-coil technology may offer advantages for negative symptoms by reaching deeper prefrontal structures. Being studied for broader schizophrenia applications.
• NeuroStar (Neuronetics) — Can deliver DLPFC protocols for negative symptoms using the same approach as depression. Less commonly used for TPJ hallucination protocols.
• Nexstim NBS System — MRI-guided neuronavigation for precise TPJ targeting. The TPJ varies anatomically between people, so image-guided targeting may outperform landmark-based positioning.

For hallucination protocols: systems with reliable 1 Hz stimulation and neuronavigation are preferred. For negative symptoms: any system delivering standard high-frequency DLPFC stimulation works.

Cost and Insurance Coverage

TMS for schizophrenia is not covered by insurance — no FDA approval for hallucination or negative symptom indications. Out-of-pocket costs: $6,000 to $15,000 for a full course.

Ways to access treatment:

• Clinical trials are the most accessible route. Academic psychiatry departments frequently run TMS studies for hallucinations and negative symptoms, with treatment at no cost. Search ClinicalTrials.gov for “TMS schizophrenia” or “TMS hallucinations.”
• The depression overlap: Depression is common in schizophrenia (25-40%). If depression criteria are met, insurance may cover TMS under that diagnosis, with potential secondary benefits for negative symptoms (which overlap significantly with depressive symptoms).
• University-affiliated TMS labs may offer reduced-cost treatment for people who consent to outcome tracking and data collection.
• State mental health programs in some states cover innovative treatments for treatment-resistant conditions. Check with your state’s mental health authority.
• Payment plans are available at most clinics.

Given the burden of treatment-resistant schizophrenia symptoms — disability, unemployment, extensive healthcare use — the cost may be justified if TMS produces meaningful improvement and functional gains.

Finding a TMS Provider

TMS for schizophrenia is highly specialized. You need providers with expertise in psychotic disorders, not just general TMS training.

What to look for:

• A psychiatrist experienced in treating schizophrenia who is also trained in TMS
• Familiarity with TPJ localization and hallucination-specific protocols
• Experience managing schizophrenia-specific safety considerations (medication interactions, seizure risk, behavioral challenges)
• Ability to coordinate closely with your treating psychiatrist
• Access to standardized symptom rating scales for tracking response

Questions to ask:

• How many schizophrenia patients have you treated with TMS?
• Do you use neuronavigation to target the temporoparietal junction?
• What outcomes have your patients with auditory hallucinations experienced?
• How do you manage seizure risk in patients on clozapine?
• Do you coordinate with my current psychiatrist?

Where to find treatment:

• Academic psychiatry departments with schizophrenia research programs — this is the main venue
• University-affiliated TMS research labs focused on psychotic disorders
• Clinical trials — ClinicalTrials.gov lists active studies
• VA medical centers with schizophrenia treatment and neuromodulation programs
• Never adjust or stop antipsychotic medications based on TMS response without explicit guidance from your treating psychiatrist

Frequently Asked Questions

Will TMS make my voices go away completely? Complete elimination is possible but not the typical outcome. Most responders experience a significant reduction — voices become quieter, less frequent, or less distressing. About 30-50% of people with treatment-resistant hallucinations achieve meaningful improvement. Some find that after TMS, they can more easily ignore or manage voices, even if the voices don’t fully disappear.

Is TMS safe if I’m taking clozapine? Clozapine lowers seizure threshold significantly, creating added risk with TMS. This isn’t an absolute contraindication, but it requires careful risk-benefit analysis by an experienced clinician. Stimulation intensity may be reduced and monitoring enhanced. Discuss this specifically with both your prescribing psychiatrist and TMS provider.

Can TMS replace my antipsychotic medication? No. TMS is always an add-on in schizophrenia, never a replacement for antipsychotics. Stopping antipsychotics can trigger psychotic relapse, which can be dangerous and lead to hospitalization. TMS targets specific residual symptoms that medications haven’t fully controlled.

How long do the benefits of TMS last for hallucinations? Effects typically last 2-8 weeks after completing a course, though some people experience longer-lasting benefits. Maintenance sessions (weekly or biweekly) can help sustain improvements. Research on optimal maintenance schedules is still ongoing.

My family member has schizophrenia but is suspicious of the treatment. Can TMS still work? Paranoia about the device is a practical challenge. If someone believes it will harm them, read their thoughts, or control them, safe and ethical treatment may not be possible. Building trust through education, visiting the clinic to see the equipment, and having a trusted clinician present can help. If paranoia remains a significant barrier, it may need to be addressed through medication adjustments before trying TMS.